Virtual 2020

---

Interstitial lung diseases

State of the art session
Chairs: C. Robalo Cordeiro (Coimbra, Portugal), N. Ubags (Epalinges, Switzerland)
Aims: Several task forces and position-statement papers are approved, submitted or ongoing in our Assembly 12. This session is going to discuss the major developments in the field through un update of the current TFs. Moreover, a collaboration with ATS of WASOG is ongoing for some for some of them. It would be exciting to have presented all together in a session with top quality speakers form Europe and beyond. The following projects will be discussed: 1. Diagnosis and treatment of hypersensitivity pneumonitis remain a real challenge; this talk-TF provides an overview of our current understanding and points out new opportunities for further research. 2. Genetics in ILDs: There is a growing body of evidence that both common and rare genetic variants contribute to the development and clinical manifestation of many of the ILDs. Here, we review the current understanding of genetic risk and ILD. 3. Sarcoidosis: or IPF and Lung Cancer; in preparation of a Consensus Statement; the results of the ERS Survey (speakers: Dan Culver or Carlo Vancheri) : in case that Sarcoidosis Diagnostic Guidelines and Treatment TF ae presented in a separate section 4. Interventional Pulmonology and ILDs.

Chronic Hypersensitivity pneumonitis: risks factors and therapeutic options A. Wells (London, United Kingdom)
Genetics in ILDs: what does the future hold? M. Molina Molina (Barcelona, Spain)
Invasive approaches in the diagnosis of ILDs C. Ravaglia (Forlì, Italy)
How systemic inflammatory diseases affect the lung M. Kreuter (Heidelberg, Germany)